直接抗病毒药物治疗失败后丙型肝炎基因1-3型再治疗的疗效
该研究分析第一代直接抗病毒药物(DAA)联合治疗失败后再次治疗的患者,探讨再治疗方案选择。背景指出DAA失败后常见耐药相关替代(RAS),尤其NS5A RAS影响再治疗选择,第二代方案VOX/VEL/SOF已获批但资源有限地区不可及,故第一代DAA再治疗推荐很重要。
要点
- DAA失败后常见RAS,NS5A RAS可能影响再治疗选择
- 第二代方案VOX/VEL/SOF已获批用于DAA失败后再治疗
- 许多资源有限国家无法获得第二代方案,第一代DAA再治疗推荐重要
核心结论
- 研究旨在分析第一代DAA联合治疗失败后再次治疗的患者
研究设计与样本
- 研究设计与样本量原文未报告
主要发现
- 原文未报告具体疗效数值
关键数值与推荐
- 原文未报告具体推荐条款或数值标准
临床怎么用
- 在资源有限或保险不覆盖第二代方案时,第一代DAA再治疗方案选择需参考相关推荐
局限性
- 使用第一代DAA再治疗DAA失败患者的数据有限
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA failure patients using first-generation DAAs are limited.4-7 Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.8 However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.
引用
- Dietz J, Spengler U, Müllhaupt B, et al. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clin Gastroenterol Hepatol. 2019. PMID: 31706062. doi:10.1016/j.cgh.2019.10.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。